Turkish radiopharmaceutical developer Eczacibasi Monrol has entered the theranostics market with the introduction of Lutec (lutetium-177 chloride), a radiopharmaceutical precursor.
Lutec, which is compliant with European Pharmacopoeia standards, can be used to radiolabel carrier molecules for treating cancers such as neuroendocrine and prostate tumors, according to the firm. The company said it has 12 production facilities: five in Turkey and seven worldwide.
